Crohn's disease
G Roda, S Chien Ng, PG Kotze, M Argollo… - Nature Reviews …, 2020 - nature.com
Crohn's disease is an inflammatory bowel disease that is characterized by chronic
inflammation of any part of the gastrointestinal tract, has a progressive and destructive …
inflammation of any part of the gastrointestinal tract, has a progressive and destructive …
Risk of surgery for inflammatory bowel diseases has decreased over time: a systematic review and meta-analysis of population-based studies
Background & Aims The inflammatory bowel diseases (IBDs) are chronic diseases that often
require surgery. However, the risk of requirement of surgery over time has not been well …
require surgery. However, the risk of requirement of surgery over time has not been well …
Etrolizumab as induction and maintenance therapy for ulcerative colitis in patients previously treated with tumour necrosis factor inhibitors (HICKORY): a phase 3 …
Background Etrolizumab is a gut-targeted, anti-β7 integrin, monoclonal antibody. In an
earlier phase 2 induction study, etrolizumab significantly improved clinical remission …
earlier phase 2 induction study, etrolizumab significantly improved clinical remission …
The second European evidenced-based consensus on reproduction and pregnancy in inflammatory bowel disease
CJ Van der Woude, S Ardizzone… - Journal of Crohn's …, 2015 - academic.oup.com
Trying to conceive and being pregnant is an emotional period for those involved. In the
majority of patients suffering from inflammatory bowel disease, maintenance therapy is …
majority of patients suffering from inflammatory bowel disease, maintenance therapy is …
Etrolizumab versus adalimumab or placebo as induction therapy for moderately to severely active ulcerative colitis (HIBISCUS): two phase 3 randomised, controlled …
DT Rubin, I Dotan, A DuVall, Y Bouhnik… - The lancet …, 2022 - thelancet.com
Background Etrolizumab is a gut-targeted anti-β7 integrin monoclonal antibody. In an earlier
phase 2 induction study, etrolizumab significantly improved clinical remission relative to …
phase 2 induction study, etrolizumab significantly improved clinical remission relative to …
Etrolizumab versus infliximab for the treatment of moderately to severely active ulcerative colitis (GARDENIA): a randomised, double-blind, double-dummy, phase 3 …
S Danese, JF Colombel, M Lukas… - The lancet …, 2022 - thelancet.com
Background Etrolizumab is a gut-targeted anti-β7 integrin monoclonal antibody. In a
previous phase 2 induction study, etrolizumab significantly improved clinical remission …
previous phase 2 induction study, etrolizumab significantly improved clinical remission …
European evidence based consensus on surgery for ulcerative colitis
T Øresland, WA Bemelman… - Journal of Crohn's …, 2015 - academic.oup.com
The goal of this consensus initiated by the European Crohn's and Colitis Organisation
(ECCO) was to establish European consensus guidelines for the surgical treatment of …
(ECCO) was to establish European consensus guidelines for the surgical treatment of …
Second N-ECCO consensus statements on the European nursing roles in caring for patients with Crohn's disease or ulcerative colitis
1.1. Aim The overarching aim of ECCO is to improve the care of patients with IBD through
the development of guidelines, education and research. Current evidence is fundamental in …
the development of guidelines, education and research. Current evidence is fundamental in …
Etrolizumab for maintenance therapy in patients with moderately to severely active ulcerative colitis (LAUREL): a randomised, placebo-controlled, double-blind, phase …
S Vermeire, PL Lakatos, T Ritter, S Hanauer… - The Lancet …, 2022 - thelancet.com
Background Etrolizumab is a gut-targeted anti-β7 integrin monoclonal antibody. In a
previous phase 2 induction study, etrolizumab significantly improved clinical remission …
previous phase 2 induction study, etrolizumab significantly improved clinical remission …
Surgical rates for Crohn's disease are decreasing: a population-based time trend analysis and validation study
Objectives: Temporal changes for intestinal resections for Crohn's disease (CD) are
controversial. We validated administrative database codes for CD diagnosis and surgery in …
controversial. We validated administrative database codes for CD diagnosis and surgery in …